Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Apimeds Pharmaceuticals US, Inc. (APUS) had Stock-Based Compensation of $3.27M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-6.00M |
|
-- |
|
-- |
|
$11.91M |
|
$-11.91M |
|
$5.91M |
|
$-6.00M |
|
$-12.01M |
|
$-6.00M |
|
$-6.00M |
|
$-6.00M |
|
$-12.01M |
|
$-11.91M |
|
$-11.91M |
|
10.88M |
|
10.88M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$13.98M |
|
$0.05M |
|
$150.20M |
|
$164.18M |
|
$10.71M |
|
-- |
|
$0.13M |
|
$10.84M |
|
$153.27M |
|
$3.46M |
|
$153.35M |
|
12.58M |
|
| Cash Flow Statement Financials | |
$-8.93M |
|
$-10.06M |
|
$20.62M |
|
$8.00M |
|
$9.64M |
|
$1.63M |
|
|
Stock-Based Compensation |
$3.27M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.31 |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.92% |
|
-173.32% |
|
-3.66% |
|
-3.91% |
|
$12.19 |
|
$-0.83 |
|
$-0.82 |
|